Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Edasalonexent

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Catabasis Top-Line Results for the Ph3 PolarisDMD Trial of Edasalonexent
    Catabasis Top-Line Results for the Ph3 PolarisDMD Trial of Edasalonexent

    27 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201026005834/en

    BUSINESSWIRE
    27 Oct 2020
    Share Share
    Catabasis Pharma to Present in Virtual 25th International Congress of WMS
    Catabasis Pharma to Present in Virtual 25th International Congress of WMS

    23 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200923005114/en

    BUSINESSWIRE
    23 Sep 2020
    Share Share
    Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
    Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy

    12 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200512005148/en

    BUSINESSWIRE
    12 May 2020
    Share Share
    Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
    Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy

    12 May 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/catabasis-pharmaceuticals-presents-edasalonexent-a-potential-foundational-therapy-for-duchenne-muscular-dystrophy/

    BIOSPACE
    12 May 2020
    Share Share
    Catabasis Pharma Announces the Phase 3 PolarisDMD Trial of Edasalonexent
    Catabasis Pharma Announces the Phase 3 PolarisDMD Trial of Edasalonexent

    30 Sep 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/catabasis-pharmaceuticals-announces-the-phase-3-polarisdmd-trial-of-edasalonexent-in-duchenne-muscular-dystrophy-has-exceeded-target-enrollment/

    BIOSPACE
    30 Sep 2019
    Share Share
    Catabasis Pharmaceuticals Announces Pricing of $20 Million Public Offering
    Catabasis Pharmaceuticals Announces Pricing of $20 Million Public Offering

    06 Feb 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190206005401/en

    BUSINESSWIRE
    06 Feb 2019
    Share Share